BMS, AstraZeneca, Novartis Add to 2024 M&A Upswing

BMS, AstraZeneca, Novartis Add to 2024 M&A Upswing

Source: 
BioSpace
snippet: 

After a slow 2022 and early part of 2023, the pace of mergers and acquisitions in the pharmaceutical and biotech sectors has accelerated since the middle of last year, highlighted by Pfizer’s $43 billion takeover of Seagen. Since the calendar turned to 2024, we have seen some blockbusters, including Novo Nordisk's $16.5 billion purchase agreement for Catalent and the closing of Bristol Myers Squibb's $4.8 billion acquisition of Mirati Therapeutics.